Evidence map›Paper›PMID 30143565›Full record

ArticleNeurology2018

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

Luciana Midaglia, Margarida Gratacòs, Edoardo Caronna, Nuria Raguer, Jaume Sastre-Garriga, Xavier Montalban, Mar Tintoré

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luciana MidagliaFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada. lmidaglia@cem-cat.org.
Margarida GratacòsFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.
Edoardo CaronnaFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.
Nuria RaguerFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.
Jaume Sastre-GarrigaFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.
Xavier MontalbanFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.
Mar TintoréFrom the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlemtuzumabFemaleHumansImmunologic FactorsMultiple SclerosisMyasthenia GravisYoung AdultAlemtuzumabImmunologic Factors

Identifiers

PMID30143565
PMCPMC6161544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.